Effectiveness and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-analysis

Wenchun Qu, Zhen Wang, Erica Engelberg-Cook, Abu Bakar Siddik, Guojun Bu, Julie G. Allickson, Eva Kubrova, Arnold I. Caplan, Joshua M. Hare, Camillo Ricordi, Carl J. Pepine, Joanne Kurtzberg, Jorge M. Pascual, Jorge M. Mallea, Ricardo L. Rodriguez, Tarek Nayfeh, Samer Saadi, Elaine M. Richards, Keith March, Fred P. Sanfilippo
doi: https://doi.org/10.1101/2021.10.05.21264559

ABSTRACT

MSC (a.k.a. mesenchymal stem cell or medicinal signaling cell) cell therapies have shown promise in decreasing mortality in ARDS and suggest benefits in treatment of COVID-19 related ARDS. We performed a meta-analysis of published trials assessing the effectiveness and adverse events (AE) of MSC cell therapy in individuals hospitalized for COVID-19. Systematic searches were performed in multiple databases through April 8th, 2021. Reports in all languages including randomized clinical trials (RCTs), comparative observational studies, and case series/case reports were included. Random effects model was used to pool outcomes from RCTs and comparative observational studies. Outcome measures included all-cause mortality, serious adverse events (SAEs), AEs, pulmonary function, laboratory and imaging findings. A total of 413 patients were identified from 25 studies, which included 8 controlled trials (3 RCTs), 5 comparative observational studies, (n=300) and 17 case-series/case reports (n=113). The patients age was 60.5 years (mean), 33.7% were women. When compared with the control group, MSC cell therapy was associated with reduction in all-cause mortality (RR=0.31, 95% CI: 0.12 to 0.75, I2=0.0%; 3 RCTs and 5 comparative observational studies, 300 patients), reduction in SAEs (IRR=0.36, 95% CI: 0.14 to 0.90, I2=0.0%; 3 RCTs and 2 comparative studies, n=219), no significant difference in AE rate. A sub-group with pulmonary function studies suggested improvement in patients receiving MSC. These findings support the potential for MSC cell therapy to decrease all-cause mortality, reduce SAEs, and improve pulmonary function compared to conventional care. Large scale double-blinded, well-powered RCTs should be conducted to further explore these results.

INTRODUCTION

As of August 2021, the pandemic caused by COVID-19 (SARS-CoV-2) has infected more than 200 million and contributed to the death of more than 4 million individuals worldwide.1 While the rapid development of effective vaccines is helping to mitigate this pandemic, there is a rising incidence of infection with the more highly transmissible Delta variant that is expected to increase COVID related diseases, and is capable of breakthrough disease in vaccinated individuals.2 To date, most (81%) infected patients have a mild to moderate disease course and recover within two or three weeks.3 However, among patients requiring hospitalization the mortality ranges from 5 to 17%4, 5 and among those requiring ICU admission, range from 26 to 78%.6,7Additionally, emerging new variants of the virus have raised concerns about vaccine efficacy2, 8, virus transmissibility, susceptibility and disease severity.9 Although viral mutation occurs in a natural cycle, often including removal of lethal or deleterious variants from the pool, new variants will likely extend the duration of the pandemic.9

In severe cases, SARS-CoV-2 leads to fatal acute respiratory distress syndrome (ARDS) with diffuse alveolar damage and cellular fibromyxoid exudate associated with monocyte and macrophage infiltration.10, 11 Respiratory distress typically arises 7 to 10 days post-symptom onset, with manifestations of immune dysregulation including cytokine release syndrome [IL-1, IL-6, IL-8, IL2R, IL-10, and tumor necrosis factor-α (TNF-α)], also known as “cytokine storm”, lymphopenia (CD4+ and CD8+ T cells), and decreased interferon-γ (INF-γ) expression in CD4+ T cells.11, 12 The inverse correlation between cytokine storm and lower CD4+ and CD8+ counts suggests that the cytokine response may dampen adaptive immunity.13

Treatments for patients with respiratory complications from COVID infection have evolved since the onset of the pandemic. These have focused on supportive approaches including mechanical ventilation, high-flow nasal oxygen, and ECMO, convalescent plasma, as well as anti-inflammatory and immuno-modulatory therapies ranging from corticosteroids to monoclonal antibodies targeting specific cytokines such as IL-6.14, 15 While several drug therapies have suggested promising results14, 15, their potential benefits must be balanced with concerns about side effects and secondary infections.14 New treatments focused on mitigating the underlying cellular and molecular mediators of diseases are urgently needed to address the pathophysiological processes that lead to death or long-term sequelae.

MSC cell therapies have shown promise in modulating responses in inflammatory diseases.16–18 Previously known as “mesenchymal stem cells” or “mesenchymal stromal cells” and more recently as “medicinal signaling cells,”19 MSCs are small spindle shaped cells found in the extracellular matrix and are most commonly sourced from bone marrow, adipose tissue, and umbilical cord and they can also be isolated from other tissues.20 They express the cell surface markers CD44, CD90, CD105 but do not express CD34, CD45 or HLA-DR.21 MSCs home to sites of injury and inflammation where they exert immunomodulatory effects, largely via a paracrine mode of action.22, 23 Their immunomodulatory activity arises through several well characterized effects that include: (a) suppression of proliferation and action of B cells, T cells, natural killer cells, and dendritic cells; (b) polarization of monocytes to anti-inflammatory M2 macrophages; (c) differentiation of T effector cells towards Treg cells; and (d) modulation of cytokine secretion towards increased production of IL-4, IL-10 with reduced production of TNF-α, IL-12 and IL-6.16, 21, 24, 25 MSCs may also enhance tissue repair and regeneration by secretion of factors that limit apoptosis and foster endogenous progenitor cell cycling.26, 27

With regard to the lung, MSC cell therapy has been shown to repair lung epithelium by increasing alveolar ATP, transferring mitochondria to the damaged alveolar epithelium28, maintaining balance in the renin-angiotensin system, and improving endogenous repair of pulmonary endothelial cells by enhancing their microenvironment. They also improve the alveolar-capillary barrier function of the lung22, 29, 30. Studies of COVID-19 patients suggest that MSC cell therapy can reduce inflammation by ameliorating anti-inflammatory and trophic factor expression with notable decreases in C-reactive protein (CRP), TNF-α, and cytokine-secreting immune cells.31, 32 In addition, MSCs have powerful antifibrotic effects and may alleviate pulmonary fibrosis.33 Finally, MSCs demonstrate antimicrobial activity via enhanced production of peptide cathelicidin/LL-37 production34, which also has antiviral activity.35 Preclinical study suggests that MSCs have antimicrobial properties in vivo and thus may limit microbial superinfections in the context of viral infections.36

Clinically, MSC cell therapy has been studied in viral and non-viral-induced ARDS, and appears to reduce mortality.16 Importantly, early data from the pandemic suggested that infusion of various MSC preparations could potentially reduce COVID-19 mortality and morbidity37. However, these initial clinical reports had small patient numbers and limited outcome measures. To address this issue, we conducted a systematic review of the current literature on safety, efficacy, and cytokine responses to MSC cell therapy in patients with COVID-19 infections.

METHODS

Search strategy

An extensive search of databases from the database inception to April 8th, 2021 in all languages was performed. Databases included EBM Reviews – Cochrane Central Register of Controlled Trials, EBM Reviews – Cochrane Database of Systematic Reviews, Ovid MEDLINE, Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Scopus. A medical reference librarian developed and implemented the search strategy, with feedback from the investigators. Controlled vocabulary supplemented with keywords were used to search for MSC cell therapy for patients with COVID-19 or SARS-CoV-2 infection. The exact strategy is available in Appendix A.

Eligibility criteria

We included all published randomized clinical trials, comparative observational studies and case series/case reports that evaluated the safety and/or effectiveness of stem cells administered to patients hospitalized with COVID-19 or SARS-CoV-2 infection. Studies were excluded if original data were not reported (such as a narrative review, editorials, or erratum). The detailed inclusion and exclusion criteria were listed in Appendix Table A1.

Outcome measures

The outcomes of interest included all-cause mortality, serious adverse events (SAEs) and mild adverse events (AEs). SAEs and AEs were defined according to the original studies or CBER criteria38. Mortality was reported as a separate outcome and not included in SAEs in this review.

Other evaluated outcomes included pulmonary functional measures [e.g., PaO2/ FiO2 ratio and oxygenation index; laboratory measures including lymphocyte count, D-dimer, procalcitonin (PCT), CRP, IL-6; and imaging findings including computed tomographic (CT) of the lung].

Study selection process

Independent reviewers, working in pairs, screened the titles and abstracts of all citations. Studies included by either reviewer were retrieved for full-text screening. Independent reviewers, again working in pairs, screened the full-text version of eligible studies. Conflicts between the reviewers were resolved by a third senior investigator (Figure 1).

FIGURE 1:
FIGURE 1: PRISMA 2009 flow diagram

Data collection

A pilot-tested standardized data extraction form was used to extract data. Independent reviewers extracted study details. An additional reviewer reviewed data extraction and resolved conflicts.

Risk of bias

We used the Cochrane Collaboration’s Risk of Bias 2 tool to assess risk of bias for RCTs39, the Newcastle-Ottawa tool for comparative observational studies,40 and the risk of bias tool developed by Murad et.al for case series/case report.41

Statistical analysis

To evaluate the comparative effectiveness of MSC cell therapy versus control groups, we calculated relative risk (RR) for mortality and incidence rate ratio (IRR) for SAEs and AEs from RCTs and comparative observational studies. The DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction was used to combine effect size from included studies.42 Treatment group continuity corrections were used to adjust double-zero-event studies (i.e., 0 event in both groups).43 Heterogeneity between studies was evaluated with the I2 indicator. Two-tailed p value<0.05 was considered as statistically significant. All statistical analyses were conducted using Stata version 17 (StataCorp LLC, College Station, TX).

RESULTS

The literature search identified 4852 distinct citations. Twenty-five studies with a total of 413 unique patients met the inclusion and exclusion criteria and were included in the analyses as shown in Figure 1.

Of the 25 included studies, we included 3 RCTs,37, 44, 45 5 comparative observational studies,46–50 and 17 case-series/case reports.51–67 The studies were conducted in seven countries, including Asia (n=16), Europe (n=6), North America (n=2), and South America (n=1).

The overall average age of the participants was 60.5 years (range: 19 to 83 years), with 139 (33.7%) female. Among the patients, 133 (32.2%) were deemed as “critically ill”, 268 (64.9%) “severely ill”, and only 12 (2.9%) “moderately ill”. Hypertension, diabetes mellitus and obesity were the most 3 common comorbidities (Table 1). The follow-up durations were reported in 21 studies (n=333) ranging between 4 days to 196 days after the onset of treatment.

View this table:
TABLE 1: Patient and product characteristics

The overall risk of bias was deemed low for RCTs and high for comparable and single-arm observational studies (Appendix Table A2-4).

Intervention characteristics

Allogeneic culture-expanded MSCs were used in all 25 studies (n= 255 patients), of which MSCs were derived from umbilical cord in 14 studies (n=157), menstrual blood in 3 studies (n=29), bone marrow in 1 study (n=1), adipose tissue in 1 study (n=13), heart tissue in 1 study (n=6), combined placenta (n=5)and umbilical cord (n= 6)in 1 study, and non-specified sources in 4 studies (n=38). MSCs were administered via the systemic intravenous (IV) route in 23 studies (n=253), combined IV and intratracheal routes in 1 study (n=1), and combined IV and intrathecal routes in 1 study (n=1). The dose of MSCs was weight-adjusted ranging from 1 to 3 million cells per kilogram body weight in 15 studies (n=107). Eight studies (n=146) used a fixed dose between 30 million to 200 million MSCs. One study (n=1) used 2000U and 3000U MSCs, with undefined units.57 One study (n=1) did not report the cell dose.59 Frequency of the doses used are between 1 to 5 (Table 1). Patients in treatment groups received MSC cell therapy in addition to institutionally defined standard of care while patients in reference groups received institutionally defined standard of care only.

Mortality

When compared to the control group, MSC cell therapy administration was associated with reduced mortality (RR=0.31, 95% CI: 0.12 to 0.75, I2=0.0%; 3 RCTs and 5 comparative observational studies, 300 patients; Figure 2). In all 25 studies including case series and case reports, 21 patients (8.2%) who received MSC cell therapy died.

FIGURE 2:
FIGURE 2: Mortality

Serious Adverse Events

MSC cell administration was associated with fewer SAEs compared to control group (IRR=0.36, 95% CI: 0.14 to 0.90, I2=0.0%; 3 RCTs and 2 comparative observational studies, 219 patients; Figure 3). Of all 24 studies that reported SAEs, a total of 33 incidences of SAEs were reported in 250 patients who received MSC cell therapy.

FIGURE 3:
FIGURE 3: Serious adverse events

Adverse Events

No significant difference in AEs was found between MSC cell administration group and control group (IRR=0.86, 95% CI: 0.53 to 1.38, I2=32.6%; 3 RCTs and 2 comparative observational studies, 219 patients; Figure A1). Of all 23 studies that reported AEs, a total of 172 incidences of AEs were reported in 234 patients who received MSC cell therapy.

Pulmonary and systemic changes

Longitudinal assessments of PaO2 to FiO2 ratios before and after MSC cell therapy was reported in 12 patients with MSC cell therapy, of whom 8 (66.7%) showed increased PaO2/FiO2, 4 (33.3%) patients showed decreased PaO2/FiO2 (Table 2).

View this table:
TABLE 2: Pulmonary, laboratory and imaging outcomes

Laboratory findings in patients

IL-6 level was reported in 20 patients with MSC cell therapy, of whom 17 (85%) reported a decrease. WBC count was reported in 14 patients with MSC cell therapy, with an increase in 7 (50%). D-dimer was reported in 24 MSC cell therapy patients with a decrease in 13 (54.2%) (Table 2).

CT findings

CTs of the lungs were reported in 69 patients with MSC cell therapy, of whom improvement was reported in 64 (92.7%) patients, and no improvement/change in 5 (7.3%) patients (Table 2).

DISCUSSION

This systematic review and meta-analysis evaluated 413 patients hospitalized for COVID-19. Of the 300 patients evaluated in 3 RCTs and 5 comparative observational studies, MSC cell administration was associated with significant reduction in all-cause mortality risk by 69%. MSC cell therapy was also associated with significant reduction of SAE risk by 64%. There was no significant difference in the occurrence of mild AEs. Of all patients who have received MSC cell therapy, pulmonary function was reported in 12 patients, showing improvement in 8 patients and worsening in 4 patients. IL-6 level was reported in only 20 patients, showing increase in 3 patients and decrease in 17 patients. Lung CTs showed improvement in 64 of the 69 patients reported.

Hospitalized COVID-19 patients are at significant risk of developing ARDS, multi-organ dysfunction syndrome, and acute respiratory failure that is associated with a poor prognosis. Those complications are thought to be the consequence of enhanced inflammation with inflammatory cytokine production and immune dysfunction triggered by SARS-CoV-2 infection.68–70 MSC cell therapy has been a focus of investigation because of its immunomodulatory effect that has been hypothesized to down regulate and suppress the inflammatory processes in COVID-19 patients.16

Safety is a critical issue for any new treatment, particularly in patients at high risk of death from the disease being managed. This analysis suggests a favorable safety profile with reduction of SAEs and no change in AEs in patients receiving MSC cell therapy. This safety profile is consistent with findings of other cell-based therapy trials targeting various pathologies.71–74 It is unlikely that these findings were affected by age differences between the treated and untreated groups, since the baseline ages were comparable (60.5 years of age in therapy groups and 60.4 years in control groups); this is important because older age is associated with increased rates of mortality from COVID-19.75, 76

Other outcomes examined included pulmonary function, clinical outcomes, and immune responses. Eighteen studies reported improvement of opacity in chest computed tomography within days of treatment. The improvement in pulmonary function and imaging findings also support further investigation of using MSC cell therapy for ARDS, especially in COVID-19 infected patients.

The findings from this meta-analysis also suggest beneficial effects of cell-based therapy on vital immunologic and inflammatory processes contributing to organ injury in SARS-CoV-2-infected patients. Seventeen of the studies reported reduction of inflammatory biomarkers after MSC cell therapy. MSC treatment appeared to mitigate the effects of cytokine release syndrome, a pathophysiological process in ARDS, and multi-organ dysfunction syndrome in severe cases of COVID-19. These findings suggest a potential mechanism of action and are consistent with previous results of preclinical and clinical studies for other diseases.25

Several important conclusions emerged from this review of the outcomes of MSC cell therapy for COVID-19. First, these data confirm previous findings of the low risks associated with MSC cell therapy. Our findings, combined with comparable studies treating various conditions provide strong support for MSC cell therapy having a favorable safety profile, even in this seriously ill population.72–74, 77 Second, MSC cell therapy was associated with markedly reduced mortality and SAEs in hospitalized COVID-19 patients. Among the patients included in this study, the risk of death in the group treated with MSC cell therapy was lowered by 69%. Third, although reported in limited studies, the biomarker findings support the hypothesis that MSC cell therapy reduces pathophysiologic and immunologic responses that contribute to death with SARS-CoV-2 infection.

To date, registry searches indicate that there are at least 112 clinical trials investigating the potential benefits of cell-based interventions in COVID-19 patients unresponsive to other available treatments. Nevertheless, additional larger trials are needed to further explore this promising therapeutic modality, given the limited success of other approaches to effectively manage severe cases of COVID-19. Other questions needing further study to be resolved include the best source of cells or cell products, especially for different stages of disease; the optimal dose and frequency of administration; whether the cells should be expanded in culture and, if so, for how long; and whether preconditioning the cells would improve their effectiveness. The results seen in this meta-analysis also suggest that MSC cell therapy may reduce the time to recovery and long-term complications from SARS-CoV-2 infection. Additional studies of cell-therapy in earlier phases of disease progression also are needed, especially to determine their potential ability to reduce the need for ICU admission, mechanical ventilation, and development of chronic inflammatory diseases.

Limitations

Although this analysis found a reduction in mortality associated with MSC cell therapy, it is important to note that the conclusion was derived by comparing MSC cell therapy to the institutionally defined standard of care in the early phase of the COVID-19 pandemic. More recently, refinements of therapeutic approaches and vaccinations have considerably reduced mortality. The benefit of MSC cell therapy may be reduced or absent in patients not responding to these more contemporary treatments.

CONCLUSIONS

This systematic meta-analysis demonstrates an association of MSC cell therapy with improvements in clinical outcomes, laboratory findings, and lung imaging in patients hospitalized for COVID-19, and a low incidence of adverse events related to treatment. The putative mechanisms of MSC cell therapy suggested by these and other clinical and pre-clinical studies, include beneficial modulation of inflammatory immune responses. While outcomes have improved with the changes in standard of care and vaccinations, patients continue to die from severe COVID-19. These findings support the urgent need for large, randomized double-blinded controlled trials to document the safety and efficacy of MSC cell therapy for the treatment and prevention of severe COVID-19. Appropriately designed studies would also help identify mechanisms that may potentially contribute to accelerate translation of cell-based therapies to other acute and chronic inflammatory diseases.

Data Availability

Data analyzed in this study were a re-analysis of existing data, which are openly available at locations cited in the reference section.

Authors contribution

Wenchun Qu MD, MS, PhD: Conceptualization, Formal analysis, Methodology, Writing original draft, Writing review & editing, Final approval of the manuscript

Zhen Wang PhD: Conceptualization, Formal analysis, Methodology, Writing original draft, Writing review & editing, Final approval of the manuscript

Erica Engelberg-Cook DVM, PhD: Conceptualization, Writing original draft, Writing review & editing, Final approval of the manuscript

Abu Bakar Siddik MBBS: Conceptualization, Writing original draft, Writing review & editing, Final approval of the manuscript

Guojun Bu PhD: Conceptualization, Writing review & editing, Final approval of the manuscript

Julie G. Allickson PhD: Conceptualization, Writing review & editing, Final approval of the manuscript

Eva Kubrova MD: Conceptualization, Writing review & editing, Final approval of the manuscript

Arnold I. Caplan PhD: Conceptualization, Writing review & editing, Final approval of the manuscript

Joshua M. Hare MD: Conceptualization, Writing original draft, Writing review & editing, Final approval of the manuscript

Camillo Ricordi MD: Conceptualization, Writing original draft, Writing review & editing, Final approval of the manuscript

Carl J. Pepine MD: Conceptualization, Writing original draft, Writing review & editing, Final approval of the manuscript

Joanne Kurtzberg MD: Conceptualization, Writing original draft, Writing review & editing, Final approval of the manuscript, Final approval of the manuscript

Jorge M. Pascual MD: Conceptualization, Writing review & editing, Final approval of the manuscript

Jorge M. Mallea MD: Conceptualization, Writing review & editing, Final approval of the manuscript

Ricardo L. Rodriguez MD: Conceptualization, Writing review & editing, Final approval of the manuscript

Tarek Nayfeh MD: Conceptualization, Formal analysis, Writing review & editing, Final approval of the manuscript

Samer Saadi MD: Conceptualization, Writing review & editing, Final approval of the manuscript

Elaine M. Richards PhD Conceptualization, Writing review & editing, Final approval of the manuscript

Keith March MD, PhD : Conceptualization, Writing review & editing, Final approval of the manuscript

Fred P. Sanfilippo MD, PhD : Conceptualization, Writing review & editing, Final approval of the manuscript

Conflict of interest disclosures

W. Q., J. M. H., J. K., C. R. reported roles as principal investigators of MSC trials.

J. M. H. reported having a patent for cardiac cell-based therapy, holds equity in Vestion, Inc., and maintains a professional relationship with Vestion, Inc. as a consultant and member of the Board of Directors and Scientific Advisory Board; J. M. H. is also the Chief Scientific Officer, a compensated consultant and advisory board member, for Longeveron and holds equity in Longeveron; J. M. H. is the coinventor of intellectual property licensed to Longeveron. J. M. H. declared inventor or patent holder and research funding from Longeveron, Heart Genomics; advisory role and research funding with Vestion; research funding from NHLBI.

J. K. declare Intellectual property rights with IDF, hCT-MSC for treatment of ASD, HIE, which were licensed to CryoCell Int’l by Duke University; NMDP Scientific Advisor; Celularity SAB; research funding from the Marcus Foundation, NIH, HRSA; leadership position with Istari—CMO (spouse). G. B. consults for SciNeuro and Vida Ventures, had consulted for AbbVie, E-Scape, and Eisai, and receives funding from NIH and Cure Alzheimer’s Fund. He serves as a Co-Editor-in-Chief for Molecular Neurodegeneration.

The other authors indicated no potential conflicts of interest. K.M. is a consultant in RESTEM.

View this table:
Table A1: Inclusion and exclusion criteria
View this table:
Table A2: Risk of bias – Randomized Controlled Trials (RCTs)
View this table:
Table A3: Risk of bias – Comparative observational studies
View this table:
Table A4: Risk of bias – Non-comparative studies
View this table:
TABLE A5: Severe adverse events in cell therapy group
FIGURE A1:
FIGURE A1: Adverse events

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials March 2021, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to April 8, 2021, Embase 1974 to 2021 April 08, Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily 1946 to April 08, 2021 Search Strategy:

Table
Table
Table

Scopus

  1. TITLE-ABS-KEY(((“Corona virinae” or “corona virus” or Coronavirinae or coronavirus or COVID or nCoV or hCoV) W/4 (“19” or “2019” or novel or new or nouveau or nuevo)) OR ((“Corona virinae” or “corona virus” or Coronavirinae or coronavirus* or COVID or nCoV or hCoV) and (wuhan or china or chinese or hubei)) OR (pneumon* W/3 Wuhan) OR “2019-ncov” OR “2019-novel Cov” OR “Acute Respiratory Distress Syndrome” OR ARDS OR “Corona virinae19” OR “Corona virinae2019” OR “corona virus19” OR “corona virus2019” OR Coronavirinae19 OR Coronavirinae2019 OR coronavirus19 OR “coronavirus-19” OR coronavirus2019 OR “coronavirus-2019” OR “COVID 2019” OR COVID19 OR “COVID-19” OR COVID2019 OR “cytokine storm*” OR “interstitial pneumonia*” OR MERS OR “Middle East Respiratory Syndrome” OR “ncov-19” OR nCOV19 OR nCOV2019 OR “SARS Corona virus” OR “SARS Corona virus 2” OR “SARS Coronavirus” OR “SARS-coronavirus2” OR “SARS-coronavirus-2” OR “SARS-COV” OR sarscov* OR “SARS-COV2” OR “SARS-COV-2” OR “Severe Acute Respiratory Syndrome Corona virus” OR “Severe Acute Respiratory Syndrome Corona virus 2” OR “Severe Acute Respiratory Syndrome Coronavirus” OR “Severe Acute Respiratory Syndrome Coronavirus 2” OR “viral pneumonia*” OR “virus pneumonia*”)

  2. TITLE(((coronavir* or COVID*) W/5 (pandemic* or outbreak or shutdown or “shut down*” or “shut-down*” or quarantin* or (lock* W/1 down) or “lock-down*” or lockdown* or “stay at home” or “stay-at-home” or “shelter-in-place”)))

  3. TITLE-ABS-KEY(“adipose derived stromal cell*” OR “adipose derived stromal stem cell*” OR “adipose stromal cell*” OR “adipose stromal stem cell*” OR “bone marrow derived stromal cell*” OR “bone marrow derived stromal stem cell*” OR “bone marrow stromal cell*” OR “bone marrow stromal stem cell*” OR “colony forming unit*” OR exosome* OR “Extracelullar vesicle*” OR “Induced pluripotent cell*” OR iPS OR iPSC OR “mesenchymal cell*” OR “mesenchymal progenitor cell*” OR “mesenchymal stem cell*” OR “mesenchymal stromal cell*” OR “mother cell*” OR MSC OR MSCs OR “progenitor cell*” OR “Regulatory T Cell*” OR Secretome* OR “stem cell*” OR Treg OR “umbilical cord derived stromal cell*” OR “umbilical cord derived stromal stem cell*” OR “umbilical cord stromal cell*” OR “umbilical cord stromal stem cell*” OR “wharton jelly cell*” OR “whartons jelly cell*”)

  4. PUBYEAR AFT 2018

  5. (1 or 2) and 3 and 4

  6. TITLE-ABS-KEY(“in vitro”)

  7. 5 and not 6

  8. TITLE-ABS-KEY((alpaca OR alpacas OR amphibian OR amphibians OR animal OR animals OR antelope OR armadillo OR armadillos OR avian OR baboon OR baboons OR beagle OR beagles OR bee OR bees OR bird OR birds OR bison OR bovine OR buffalo OR buffaloes OR buffalos OR “c elegans” OR “Caenorhabditis elegans” OR camel OR camels OR canine OR canines OR carp OR cats OR cattle OR chick OR chicken OR chickens OR chicks OR chimp OR chimpanze OR chimpanzees OR chimps OR cow OR cows OR “D melanogaster” OR “dairy calf” OR “dairy calves” OR deer OR dog OR dogs OR donkey OR donkeys OR drosophila OR “Drosophila melanogaster” OR duck OR duckling OR ducklings OR ducks OR equid OR equids OR equine OR equines OR feline OR felines OR ferret OR ferrets OR finch OR finches OR fish OR flatworm OR flatworms OR fox OR foxes OR frog OR frogs OR “fruit flies” OR “fruit fly” OR “G mellonella” OR “Galleria mellonella” OR geese OR gerbil OR gerbils OR goat OR goats OR goose OR gorilla OR gorillas OR hamster OR hamsters OR hare OR hares OR heifer OR heifers OR horse OR horses OR insect OR insects OR jellyfish OR kangaroo OR kangaroos OR kitten OR kittens OR lagomorph OR lagomorphs OR lamb OR lambs OR llama OR llamas OR macaque OR macaques OR macaw OR macaws OR marmoset OR marmosets OR mice OR minipig OR minipigs OR mink OR minks OR monkey OR monkeys OR mouse OR mule OR mules OR nematode OR nematodes OR octopus OR octopuses OR orangutan OR “orang-utan” OR orangutans OR “orang-utans” OR oxen OR parrot OR parrots OR pig OR pigeon OR pigeons OR piglet OR piglets OR pigs OR porcine OR primate OR primates OR quail OR rabbit OR rabbits OR rat OR rats OR reptile OR reptiles OR rodent OR rodents OR ruminant OR ruminants OR salmon OR sheep OR shrimp OR slug OR slugs OR swine OR tamarin OR tamarins OR toad OR toads OR trout OR urchin OR urchins OR vole OR voles OR waxworm OR waxworms OR worm OR worms OR xenopus OR “zebra fish” OR zebrafish) AND NOT (human OR humans or patient or patients))

  9. 7 and not 8

  10. TITLE-ABS-KEY(newborn* or neonat* or infant* or toddler* or child* or adolescent* or paediatric* or pediatric* or girl or girls or boy or boys or teen or teens or teenager* or preschooler* or “pre-schooler*” or preteen or preteens or “pre-teen” or “pre-teens” or youth or youths) AND NOT TITLE-ABS-KEY(adult or adults or “middle age” or “middle aged” OR elderly OR geriatric* OR “old people” OR “old person*” OR “older people” OR “older person*” OR “very old”)

  11. 9 and not 10

  12. DOCTYPE(ed) OR DOCTYPE(bk) OR DOCTYPE(er) OR DOCTYPE(no) OR DOCTYPE(sh)

  13. 11 and not 12

  14. INDEX(embase) OR INDEX(medline) OR PMID(0* OR 1* OR 2* OR 3* OR 4* OR 5* OR 6* OR 7* OR 8* OR 9*)

  15. 13 and not 14

ClinicalTrials.Gov

Condition or disease

(“2019 novel coronavirus” OR “2019-nCoV” OR “acute respiratory distress” OR “acute respiratory syndrome” OR ARDS OR Coronavirus OR “COVID 19” OR “cytokine storm” OR “interstitial pneumonia” OR MERS OR “Middle East Respiratory Syndrome” OR “SARS-CoV”)

(“viral pneumonia” OR “virus pneumonia”)

Other terms

(“colony forming unit*” OR exosome* OR “Extracelullar vesicle*” OR “Induced pluripotent cell*” OR iPS OR iPSC OR “mesenchymal cell*” OR “mesenchymal progenitor cell*” OR “mother cell*” OR MSC OR MSCs OR “progenitor cell*” OR “Regulatory T Cell*”)

(Secretome* OR “stem cell*” OR “stromal cell*” OR Treg OR “wharton jelly cell*” OR “whartons jelly cell*”) Limited to Adults

First posting

01/01/2019 To 01/12/2021

Acknowledgments

The authors wish to acknowledge Krishnendu Roy PhD from Georgia Institute of Technology for his expert opinion that was critical for this manuscript.

References

  1. 1.↵
    Johns Hopkins University of Medicine. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Published 2021, August 8. Accessed.
  2. 2.↵
    Williams SV, Vusirikala A, Ladhani SN, et al. An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021. Euro Surveill. 2021;26(27).
  3. 3.↵
    Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. JAMA. 2020;323(15):1499–1500.
    OpenUrlPubMed
  5. 5.↵
    Macedo A, Goncalves N, Febra C. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Ann Epidemiol. 2021;57:14–21.
    OpenUrlCrossRef
  6. 6.↵
    Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581.
    OpenUrlCrossRefPubMed
  7. 7.
    Nadeem A, Hamed F, Saleh K, Abduljawad B, Mallat J. ICU outcomes of COVID-19 critically ill patients: An international comparative study. Anaesth Crit Care Pain Med. 2020;39(4):487–489.
    OpenUrl
  8. 8.↵
    Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Badley AD. The Yin and Yang of SARS-CoV-2 Mutation and Evolution. Mayo Clin Proc. 2021;96(4):863–865.
    OpenUrl
  10. 10.↵
    Xu T, Chen C, Zhu Z, et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. Int J Infect Dis. 2020;94:68–71.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis. 2020;94:81–87.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202–2205.
    OpenUrlPubMed
  14. 14.↵
    Cano EJ, Fonseca Fuentes X, Corsini Campioli C, et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2020.
  15. 15.↵
    Group WHOREAfC-TW, Shankar-Hari M, Vale CL, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021.
  16. 16.↵
    Qu W, Wang Z, Hare JM, et al. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020;9(9):1007–1022.
    OpenUrl
  17. 17.
    Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60(6):788–798.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Liang L, Dong C, Chen X, et al. Human umbilical cord mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid (TNBS)-induced colitis. Cell Transplant. 2011;20(9):1395–1408.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Caplan AI. Medicinal signalling cells: they work, so use them. Nature. 2019;566(7742):39.
    OpenUrl
  20. 20.↵
    Hunt C HY, Law L, Bydon M, Nassr A, Smith J, Mauch Mauck W, Eldrige J, Malanga G, Qu W. Five Generations of Cell Preparation: A translational framework for categorizing regenerative stem cell therapies. Journal of the American Academy of Regenerative Medicine. 2017;1(1).
  21. 21.↵
    Pittenger MF. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regen Med. 2019;4:1-15.
    OpenUrl
  22. 22.↵
    Kallmeyer K, Pepper MS. Homing properties of mesenchymal stromal cells. Expert Opin Biol Ther. 2015;15(4):477–479.
    OpenUrlCrossRef
  23. 23.↵
    Zhou Y, Yamamoto Y, Xiao Z, Ochiya T. The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity. J Clin Med. 2019;8(7).
  24. 24.↵
    Li X, Yue S, Luo Z. Mesenchymal stem cells in idiopathic pulmonary fibrosis. Oncotarget. 2017;8(60):102600–102616.
    OpenUrl
  25. 25.↵
    Li J, Shao Q, Zhu X, Sun G. Efficacy of autologous bone marrow mesenchymal stem cells in the treatment of knee osteoarthritis and their effects on the expression of serum TNF-alpha and IL-6. J Musculoskelet Neuronal Interact. 2020;20(1):128–135.
    OpenUrl
  26. 26.↵
    Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regen Med. 2010;5(1):121–143.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Premer C, Blum A, Bellio MA, et al. Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells. EBioMedicine. 2015;2(5):467–475.
    OpenUrl
  28. 28.↵
    Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18(5):759–765.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Qin H, Zhao A. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell. 2020;11(10):707–722.
    OpenUrlPubMed
  30. 30.↵
    Herold S, Gabrielli NM, Vadasz I. Novel concepts of acute lung injury and alveolar-capillary barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2013;305(10):L665–681.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    Rajarshi K, Chatterjee A, Ray S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnol Rep (Amst). 2020;26:e00467.
    OpenUrl
  32. 32.↵
    Li J, Wang X, Li N, et al. Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review. Curr Gene Ther. 2020;20(4):285–288.
    OpenUrl
  33. 33.↵
    Usunier B, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells Int. 2014;2014:340257.
  34. 34.↵
    Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28(12):2229–2238.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    Currie SM, Findlay EG, McHugh BJ, et al. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One. 2013;8(8):e73659.
    OpenUrlCrossRefPubMed
  36. 36.↵
    Saeedi P, Halabian R, Fooladi AAI. Antimicrobial effects of mesenchymal stem cells primed by modified LPS on bacterial clearance in sepsis. J Cell Physiol. 2019;234(4):4970–4986.
    OpenUrlCrossRef
  37. 37.↵
    Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361.
    OpenUrlCrossRefPubMed
  38. 38.↵
    U.S. Food and Drug Administration. Safety assessment in Clinical Trials and Beyond. https://www.fda.gov/media/84954/download. Published 2012. Accessed.
  39. 39.↵
    Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
  40. 40.↵
    GA Wells BS, D O’Connell, J Peterson, V Welch, M Losos, P Tugwell,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
  41. 41.↵
    Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–63.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    Rover C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. BMC Med Res Methodol. 2015;15:99.
    OpenUrlCrossRefPubMed
  43. 43.↵
    Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351–1375.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021.
  45. 45.↵
    Shi L, Huang H, Lu X, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021;6(1):58.
    OpenUrlCrossRefPubMed
  46. 46.↵
    Haberle H, Magunia H, Lang P, et al. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. J Intensive Care Med. 2021:885066621997365.
  47. 47.
    Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020;11(2):216–228.
    OpenUrlCrossRefPubMed
  48. 48.
    Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5(1):172.
    OpenUrl
  49. 49.
    Xu X, Jiang W, Chen L, et al. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med. 2021;11(2):e297.
    OpenUrl
  50. 50.↵
    Singh S, Chakravarty T, Chen P, et al. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Basic Res Cardiol. 2020;115(4):36.
    OpenUrl
  51. 51.↵
    Chen X, Shan Y, Wen Y, Sun J, Du H. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects. J Infect. 2020;81(4):647–679.
    OpenUrlCrossRefPubMed
  52. 52.
    Feng Y, Huang J, Wu J, et al. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study. Cell Prolif. 2020;53(12):e12947.
    OpenUrl
  53. 53.
    Guo Z, Chen Y, Luo X, He X, Zhang Y, Wang J. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia. Crit Care. 2020;24(1):420.
    OpenUrlCrossRefPubMed
  54. 54.
    Hashemian SR, Aliannejad R, Zarrabi M, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021;12(1):91.
    OpenUrl
  55. 55.
    Iglesias M, Butron P, Torre-Villalvazo I, et al. Mesenchymal Stem Cells for the Compassionate Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID 19. Aging Dis. 2021;12(2):360–370.
    OpenUrl
  56. 56.
    Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore). 2020;99(31):e21429.
    OpenUrlCrossRefPubMed
  57. 57.↵
    Lu J, Xie ZY, Zhu DH, Li LJ. Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature. World J Clin Cases. 2021;9(7):1705–1713.
    OpenUrl
  58. 58.
    Peng H, Gong T, Huang X, et al. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. Stem Cell Res Ther. 2020;11(1):291.
    OpenUrl
  59. 59.↵
    Sahin AS, Kaya E, Turgut G, Kocatas A. Can we use Mesenchymal Stem Cell transplantation for COVID-19 patients in puerperium period? J Turk Ger Gynecol Assoc. 2021.
  60. 60.
    Sanchez-Guijo F, Garcia-Arranz M, Lopez-Parra M, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine. 2020;25:100454.
    OpenUrl
  61. 61.
    Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med. 2020;14(5):664–673.
    OpenUrl
  62. 62.
    Tao J, Nie Y, Wu H, et al. Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient. J Infect Dev Ctries. 2020;14(10):1138–1145.
    OpenUrl
  63. 63.
    Yilmaz R, Adas G, Cukurova Z, et al. Mesenchymal stem cells treatment in COVID-19 patient with multi-organ involvement. Bratisl Lek Listy. 2020;121(12):847–852.
    OpenUrl
  64. 64.
    Zengin R, Beyaz O, Koc ES, et al. Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report. Stem Cell Investig. 2020;7:17.
  65. 65.
    Zhu Y, Zhu R, Liu K, et al. Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report. Infect Drug Resist. 2020;13:3295–3300.
    OpenUrl
  66. 66.
    Soler Rich R, Rius Tarruella J, Melgosa Camarero MT. Expanded mesenchymal stem cells: a novel therapeutic approach for SARS-CoV-2 pneumonia (COVID-19). Concepts regarding a first case in Spain. Med Clin (Engl Ed). 2020;155(7):318–319.
    OpenUrl
  67. 67.↵
    Zhang Y, Ding J, Ren S, et al. Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther. 2020;11(1):207.
    OpenUrlPubMed
  68. 68.↵
    Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions. JAMA. 2020.
  69. 69.
    Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I. COVID-19 cytokine storm: The anger of inflammation. Cytokine. 2020;133:155151.
    OpenUrlCrossRef
  70. 70.↵
    McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am J Respir Crit Care Med. 2020;202(6):812–821.
    OpenUrlCrossRefPubMed
  71. 71.↵
    Bydon M, Dietz AB, Goncalves S, et al. CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury. Mayo Clin Proc. 2020;95(2):406–414.
    OpenUrl
  72. 72.↵
    Bartolucci J, Verdugo FJ, Gonzalez PL, et al. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017;121(10):1192–1204.
    OpenUrlAbstract/FREE Full Text
  73. 73.
    Lalu MM, Mazzarello S, Zlepnig J, et al. Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. Stem Cells Transl Med. 2018;7(12):857–866.
    OpenUrl
  74. 74.↵
    Wang L, Huang S, Li S, et al. Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study. Drug Des Devel Ther. 2019;13:4331–4340.
    OpenUrl
  75. 75.↵
    Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
    OpenUrlCrossRefPubMed
  76. 76.↵
    Epidemiology Working Group for Ncip Epidemic Response CCfDC, Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–151.
    OpenUrlCrossRefPubMed
  77. 77.↵
    Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–162.
    OpenUrl
Back to top
Posted October 07, 2021.
Download PDF
Data/Code
Email
Effectiveness and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-analysis
Wenchun Qu, Zhen Wang, Erica Engelberg-Cook, Abu Bakar Siddik, Guojun Bu, Julie G. Allickson, Eva Kubrova, Arnold I. Caplan, Joshua M. Hare, Camillo Ricordi, Carl J. Pepine, Joanne Kurtzberg, Jorge M. Pascual, Jorge M. Mallea, Ricardo L. Rodriguez, Tarek Nayfeh, Samer Saadi, Elaine M. Richards, Keith March, Fred P. Sanfilippo
medRxiv 2021.10.05.21264559; doi: https://doi.org/10.1101/2021.10.05.21264559
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area